Was Douglas Carr’s Century Therapeutics (IPSC) share sale discretionary?

According to the footnote, the share sales were automatic and conducted solely to cover tax withholding obligations from restricted stock unit vesting. The filing explicitly notes that these sales were not at Douglas Carr’s discretion , indicating an administrative rather than elective transaction.

Century Therapeutics (IPSC) SVP has automatic share sale to cover RSU taxes

Q: What did Century Therapeutics (IPSC) insider Douglas Carr report in this Form 4?

Douglas Carr, SVP Finance & Operations, reported a sale of 275 common shares of Century Therapeutics at $1.977 per share on August 3, 2026, leaving him with 504819 shares directly held afterward.

Q: Why were shares of Century Therapeutics (IPSC) sold by Douglas Carr?

The 275 shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. The footnote states the sales were automatic and executed without Carr’s discretion, indicating a tax-related administrative transaction.

Q: What was the price of the Century Therapeutics (IPSC) shares sold by Douglas Carr?

The 275 Century Therapeutics common shares sold by Douglas Carr were transacted at a price of $1.977 per share . The filing describes this as a sale in the open market or a private transaction, executed automatically to satisfy tax withholding obligations.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Century Therapeutics, Inc. senior vice president of Finance & Operations Douglas Carr reported selling 275 shares of common stock on August 3, 2026 at $1.977 per share. According to the footnote, these shares were sold automatically to cover tax withholding obligations from vesting restricted stock units, and were not sold at his discretion. Following the sale, Carr directly held 504819 shares of common stock.

Insider Trade Summary

Net Seller: 275 shares

Net Sell 1 txn

Insider Carr Douglas

Role SVP Finance & Operations

Sold 275 shs ($543.68)

Type	Security	Shares	Price	Value
Sale	Common Stock ^F1	275	$1.977	$543.68

Holdings After Transaction: Common Stock — 504,819 shares (Direct)

Footnotes (1)

F1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

Key Figures

Shares sold: 275 shares Sale price: $1.977 per share Shares held after transaction: 504819 shares +1 more

4 metrics

Shares sold 275 shares Common stock sold on August 3, 2026

Sale price $1.977 per share Price for the 275 common shares sold

Shares held after transaction 504819 shares Directly owned common stock following the sale

Net insider share change 275 shares Net shares sold according to transaction summary

Key Terms

restricted stock units, tax withholding obligations, automatic

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares required to be sold ... to cover tax withholding obligations"

automatic financial

"Such sales were automatic and not at the discretion"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 04:09 PM Accepted by SEC EDGAR 08/05/2026 - 04:08 PM

FAQ

What did Century Therapeutics (IPSC) insider Douglas Carr report in this Form 4?

Douglas Carr, SVP Finance & Operations, reported a sale of 275 common shares of Century Therapeutics at $1.977 per share on August 3, 2026, leaving him with 504819 shares directly held afterward.

Why were shares of Century Therapeutics (IPSC) sold by Douglas Carr?

The 275 shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. The footnote states the sales were automatic and executed without Carr’s discretion, indicating a tax-related administrative transaction.

How many Century Therapeutics (IPSC) shares does Douglas Carr hold after the reported sale?

After the August 3, 2026 transaction, Douglas Carr directly held 504819 shares of Century Therapeutics common stock. This figure reflects his position immediately following the 275-share automatic tax-withholding sale linked to restricted stock unit vesting.

What was the price of the Century Therapeutics (IPSC) shares sold by Douglas Carr?

The 275 Century Therapeutics common shares sold by Douglas Carr were transacted at a price of $1.977 per share. The filing describes this as a sale in the open market or a private transaction, executed automatically to satisfy tax withholding obligations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carr Douglas

(Last)

(First)

(Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 12TH FLOOR

(Street)

PHILADELPHIA

PENNSYLVANIA

19104

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP Finance & Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/03/2026		S⁽¹⁾		275	D	$1.977	504,819	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

	/s/ Douglas Carr	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR